TGFB1 and pulmonary arterial hypertension: An antibody capable of inhibiting both type I and type II receptors for TGF-β was reported to be efficacious in a monocrotaline rat model of PAH (64), but such receptor immunoneutralization has not been evaluated in patients with PAH.